Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib

Nobuyoshi Hayashi; Akihisa Fujita; Toyohiro Saikai; Hirotugu Takabatake; Mie Sotoshiro; Kyuutarou Sekine; Akihiko Kawana

doi:10.2169/internalmedicine.9368-17

CASE REPORTS

Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib

Nobuyoshi Hayashi, Akihisa Fujita, Toyohiro Saikai, Hirotugu Takabatake, Mie Sotoshiro, Kyuutarou Sekine, Akihiko Kawana

Author information

Keywords: LCNEC, pulmonary neuroendocrine carcinoma, ALK rearrangement and alectinib

JOURNAL OPEN ACCESS

2018 Volume 57 Issue 5 Pages 713-716

DOI https://doi.org/10.2169/internalmedicine.9368-17

Browse “Advance online publication” version

Details

Abstract

Anaplastic lymphoma kinase (ALK) rearrangement is most commonly observed in lung adenocarcinoma in a subset of lung cancer. Large cell neuroendocrine carcinoma (LCNEC) harboring an ALK rearrangement is very rare. Based on the findings from a transbronchial lung biopsy, a 75-year-old non-smoking woman was diagnosed with LCNEC with multiple liver and bone metastases. After seven cycles of cytotoxic chemotherapy, her genotype testing demonstrated ALK rearrangement. Subsequently, she was administered alectinib and exhibited a partial response.

Corresponding author

Register with J-STAGE for free!